Preparation and evaluation of niosomes containing autoclaved

Leishmania major: a preliminary study by Pardakhty, Abbas et al.
Journal of Microencapsulation, 2012; 29(3): 219–224
 2012 Informa UK Ltd.
ISSN 0265-2048 print/ISSN 1464-5246 online
DOI: 10.3109/02652048.2011.642016
Preparation and evaluation of niosomes containing autoclaved
Leishmania major: a preliminary study
Abbas Pardakhty1, Mojtaba Shakibaie2, Hamid Daneshvar3, Ali Khamesipour4,
Tayebe Mohammadi-Khorsand5 and Hamid Forootanfar2
1Department of Pharmaceutical Sciences, Pharmaceutics Research Center, Kerman University of Medical Sciences,
P.O. Box 76175-493, Kerman, Iran, 2Department of Pharmacognosy and Biotechnology, Pharmaceutics Research
Center, Kerman University of Medical Sciences, P.O. Box 76175-493, Kerman, Iran, 3Department of Immunology,
School of Medical Sciences, Kerman University of Medical Sciences, P.O. Box 444, Kerman, Iran, 4Center for Research
and Training in Skin Disease and Leprosy, Tehran University of Medical Sciences, P.O. Box 14155-6383, Tehran 14166,
Iran, and 5Department of Pharmacognosy, Herbal and Traditional Medicines Research Center, Kerman University
of Medical Sciences, P.O. Box 76175-493, Kerman, Iran
Abstract
In this study, different positively charged niosomal formulations containing sorbitan esters, cholesterol
and cetyl trimethyl ammonium bromide were prepared by film hydration method for the entrapment of
autoclaved Leishmania major (ALM). Size distribution pattern and stability of niosomes were investigated by
laser light scattering method and ALM encapsulation per cent was measured by the bicinchoninic acid
method. Finally, the selected formulation was used for the induction of the immune response
against cutaneous leishmaniasis in BALB/c mice. Size distribution curves of all the formulations followed
a log-normal pattern and the mean volume diameter was in the range 7.57–15.80 mm. The mean volume
diameters were significantly increased by adding Tween to Span formulations (p5 0.05). The percentage of
ALM entrapped in all formulations varied between 14.88% and 36.65%. In contrast to ALM, in vivo studies
showed that the niosomes containing ALM have a moderate effect in the prevention of cutaneous
leishmaniasis in BALB/c mice.
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Introduction
A number of new vaccines containing protein subunits
or synthetic peptides exhibit low immunogenicity and so,
to increase the immune response, the adjuvants are
required (Conacher et al., 2000a). The most common
types of adjuvants used in recent years are aluminium
compounds (Alum). Such adjuvants mainly stimulate
humoral immune response and cannot effectively induce
cell-mediated immune responses (Conacher et al., 2000a;
Lindblad, 2004). Furthermore, the alum compounds
have shown some unwanted side effects. Consequently,
extensive research have been done to produce and exploit
the new adjuvants that lead to the use of vesicular
systems for the clinical study of influenza–tetanus–
diphtheria liposomal vaccine (Gregoriadis et al., 1996)
and hepatitis A liposomal vaccine (Epaxal-Berna)
(Ambrosch et al., 1997).
Liposomes were composed of phospholipids producing
special closed-layer membranes in aqueous media and they
entrapped the materials in vesicles and between the lipid
layers (Christensen et al., 2011). Liposomes showed poor
adjuvant activity which is more pronounced for antigens
with low immunogenicity (Henriksen-Lacey et al., 2011).
Address for correspondence: Mojtaba Shakibaie, Department of Pharmacognosy and Biotechnology, Pharmaceutics Research Center, Kerman University of
Medical Sciences, P.O. Box 76175-493, Kerman, Iran. Tel: þ98 341 3205015. Fax: þ98 341 3205003. E-mail: shakiba@kmu.ac.ir
(Received 11 Aug 2011; accepted 11 Nov 2011)
http://www.informahealthcare.com/mnc
219
Some phospholipids are susceptible to oxidation in the
presence of air. Hence, manufacturing, packaging and
storing of liposomes must be done in the presence of
an inert gas such as nitrogen (Jesorka and Orwar,
2008). Consequently, the use of sustainable alternatives
such as non-ionic surfactants is inevitable, especially for
creating a strong cellular immune response against intra-
cellular organisms (Perrie et al., 2008). Niosomes (non-
ionic surfactant vesicles (NISV)) are resistant to oxidation
and do not require special packaging and storing condi-
tions (Karim et al., 2010). Compared to liposomes, nio-
somes have some advantages such as chemical stability,
lower costs of the chemicals and the large amount of
surfactant classes available to design these vesicular sys-
tems (Jain and Vyas, 2006; Huang et al., 2011). Previous
studies on the adjuvant properties of niosomes exhibited
that the niosomes containing bovine serum albumin
(BSA) caused a stronger immune response than BSA for-
mulated in Freund’s complete adjuvant (Brewer and
Alexander, 1992). The soluble antigens of Toxoplasma
gondii formulated in a niosomal system produced
strong cellular immune response against toxoplasmosis
(Roberts et al., 1994).
Leishmaniasis comprises a wide range of diseases from
self-limited skin diseases to diffuse or severe visceral dis-
eases caused by different species of the genus Leishmania
(Reithinger et al., 2007). Cutaneous leishmaniasis is an
important health problem and many efforts have been con-
ducted to achieve effective vaccines (Murray et al., 2005;
Mishra et al., 2007).
According to the application of autoclaved Leishmania
major (ALM) in vaccination against cutaneous leishmania-
sis (Misra et al., 2001; Rhee et al., 2002), the aim of this study
was to formulate positively charged niosomes containing
ALM and to evaluate their physicochemical characteristics.
In the next step, the in vivo performances of the selected
formulation were examined in order to make use of the
properties of this new adjuvant against cutaneous
leishmaniasis.
Materials and methods
Materials
Non-ionic surfactants including sorbitan monolaurate
(Span 20), sorbitan monopalmitate (Span 40), sorbitan
monostearate (Span 60), sorbitan monooleate (Span 80),
polysorbate 20 (Tween 20), polysorbate 40 (Tween 40),
polysorbate 60 (Tween 60) and polysorbate 80 (Tween
80) as well as RPMI 1640 medium and foetal calf serum
(FCS) were purchased from Sigma–Aldrich (St. Louis,
MO). Cholesterol (Chol) and cetyl trimethyl ammonium
bromide (CTAB) were supplied by Fluka (Switzerland).
The ALM (7.5 108 promastigote per mL, 11.11 mg/mL of
protein) produced from promastigotes of L. major (MRHO/
IR/76/ER) was purchased from the Razi Vaccine and Serum
Research Institute, Hesarak, Iran. All other chemicals and
solvents were of analytical grade.
Preparation of NISV
For the preparation of niosomes, a modified version of lipid
hydration method was used as previously described
(Pardakhty et al., 2007). Briefly, various non-ionic surfac-
tant/Chol/CTAB ratios were used to prepare formulations
(Table 1). In this method, 150mmol of each mixture were
dissolved in 10 mL chloroform in a 100-mL round-
bottomed flask. To form a thin film on the wall of the
flask, the organic solvent was removed under reduced pres-
sure (60C, 120 rpm) by a rotary evaporator (Buchi,
Switzerland). Residual chloroform was evaporated in a
vacuum oven for 8 h at room temperature followed by the
Table 1. Composition of niosomes containing ALM, ALM encapsulation efficiency (EE%) and mean volume
diameter of vesicles at different time intervals after preparation.
Surfactant
name
Molar ratio ALM EE% SD Mean volume
diameter (mm) SD
Surfactant Cholesterol CTAB
S T 72h 3 months
S 20 6 0 3 1 36.65 1.00 9.87 0.14 59.90 0.32
S 40 6 0 3 1 32.81 1.84 10.71 0.38 14.30 0.56
S 60 6 0 3 1 27.37 1.28 9.64 0.17 9.93 0.33
S 80 6 0 3 1 27.20 0.88 8.54 0.54 40.20 0.56
T 20 0 6 3 1 14.88 2.60 8.06 0.53 11.24 0.48
T 40 0 6 3 1 26.83 1.40 7.83 0.07 10.13 0.46
T 60 0 6 3 1 28.84 1.80 11.70 0.16 44.47 0.53
T 80 0 6 3 1 15.08 1.76 7.57 0.10 10.35 0.51
S 20/T 20 3 3 3 1 26.61 0.96 11.33 0.15 10.93 0.32
S 40/T 40 3 3 3 1 33.01 1.60 10.80 0.98 11.50 0.57
S 60/T 60 3 3 3 1 33.28 0.84 12.25 0.20 13.08 0.39
S 80/T 80 3 3 3 1 29.69 2.80 9.43 0.13 9.10 0.28
Notes: S, Span; T, Tween; and CTAB, cetyl trimethyl ammonium bromide; EE%, percent of encapsulation
efficiency. Mean SD, n¼ 3.
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hydration of the dried film using 5 mL isotonic phosphate
buffered saline (PBS) (pH 7.2) containing ALM (500 mg/mL
of protein) with a mild rotation in water bath at 60C
for 30 min. The resulting multi-lamellar NISV dispersions
were left to gradually cool and stored at 4C.
Morphology and size distribution of prepared vesicles
To evaluate the formation and morphology of vesicles, the
suspensions were observed by optical microscope (Zeiss,
Germany) equipped with a computer-controlled image
analysis system in 10 40 and 10 100 magnifications.
In this study, 72 h after preparation, the particle size distri-
bution patterns of various formulations containing ALM
were determined by static laser light diffraction method
in a particle analyzer (Malvern Master Sizer X, Malvern,
UK). Measurement was carried out using a 100 mm focal
length lens, which was capable of measuring vesicles in the
0.5–180 mm size range. The fundamental size distribution
derived by this technique was volume based and the size
distribution was expressed in terms of the volumes of
equivalent spheres (dv). Size distribution parameters and
derived diameters were calculated from the fundamental
size distribution using Sizer-X software.
ALM encapsulation efficiency
To separate non-entrapped ALM, the vesicle suspensions
were centrifuged (90 XL Ultracentrifuge, Beckman, USA) at
11 000 g for 30 min at 4C and washed twice with PBS (pH
7.2). After disrupting the niosomes by isopropyl alcohol,
the amounts of ALM in the supernatant and in the pellets
were measured by Micro BCATM Protein Assay Kit (Pierce,
Rockford, IL) using a BSA standard curve. ALM encapsula-
tion efficiency (EE) was calculated as follows:
EE%¼ 100 (amount of incorporated ALM/amount of
ALM used for vesicle preparation)
Physical stability of prepared niosomes
Aggregation or fusion of the vesicles as a function of storage
duration was determined as the changes in vesicle diame-
ter by laser light scattering method. The vesicles were
stored in glass vials in refrigerator (4C) for 3 months.
The changes in morphology of niosomes and also the com-
ponent separation were evaluated by the optical micro-
scope. No special precautions were taken to improve the
stability of vesicles.
Animals and treatments
In this study, 32 male BALB/c mice (body weight 20–22 g)
were used. The mice were purchased from the Pasteur
Institute of Iran (Tehran, Iran) and housed in plastic
cages in a colony room with controlled temperature
(22 1C) and humidity (50 10%) and a 12/12 h light/
dark cycle. The mice had free access to tap water and
food. The experimental procedures carried out in this
study were in compliance with the guidelines of the
Kerman University of Medical Science (Kerman, Iran) for
the care and use of laboratory animals. The mice were
divided into control, ALM, niosomes without ALM and nio-
somes containing ALM groups and were subcutaneously
vaccinated by 0.1 mL of PBS (pH 7.2), ALM (50 mg of pro-
tein/mouse), niosomes without ALM and niosomes con-
taining ALM (50 mg of protein/mouse), respectively.
To vaccinate the mice, preparations were inoculated three
times at 2-week intervals. Leishmania major (MRHO/IR/
76/ER) were cultured in RPMI 1640 medium supplemented
with 10% (v/v) FCS at 27C in a CO2 incubator (5% CO2 and
95% relative humidity). Four weeks after the last immuni-
zation, the BALB/c mice were subcutaneously injected at
the base of tail with 0.1 mL culture media containing 1 106
stationary phase promastigotes. Finally, the mean diame-
ters of lesions were measured weekly.
Statistical analysis
Each value was expressed as the mean SD. Software SPSS
15 for windows (SPSS Inc., Chicago) was used for statistical
analysis. The differences between groups were determined
using one-way analysis of variance test and p-values less
than 0.05 were considered significant.
Results and discussion
The adjuvant activities of different non-ionic surfactants
such as Tween 80, Span 85 (Vogel and Powell, 1995) and
Span 40 and 60 (Chattaraj and Das, 2003) have been pre-
viously reported. Due to low toxicities of these compounds
(Conacher et al., 2000b), sorbitan esters (Span) and their
polyoxyethylene derivatives (Tween) were selected for
preparation of niosomes containing ALM. The ability of
surfactants to shape vesicles depends on the properties of
the surfactant such as balance between hydrophilic surface
area, the volume of the hydrocarbon chain and the maxi-
mum length that the chains can assume (Manosroi et al.,
2003). All used surfactants formed niosomes in the pres-
ence of ALM. Niosomes were uniform in size and approx-
imately spherical in shape. The micrographs in Figure 1
exhibit the formation of vesicular structures.
The presence of hydrophobic compounds with high
molecular weight such as cholesterol is essential for the
formation and stabilization of two layers in niosomes
(Baillie et al., 1985; Uchegbu and Vyas, 1998). Although
the presence of charge-inducing agents leads to the unifor-
mity and stability of the vesicles, some negatively charged
inducing compounds such as dicetyl phosphate exhibit low
adjuvant activities (Conacher et al., 2000a). Distribution of
CTAB in bilayers may increase the curvature of bilayers
through electrostatic repulsion between the ionized head
group, thus increasing the hydrophilic surface area and this
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effect will result in smaller vesicles. Vesicles containing
positive charge lead to cell-mediated immune response
(Nakanishi et al., 1997). This effect is very important for
immunity against intracellular pathogens such as L.
major. Thus, in this study, CTAB was employed as a posi-
tively charged inducing agent.
The particle sizes of different formulations are presented
in Table 1. All formulations demonstrated log-normal par-
ticle size distribution patterns. The smallest size
(7.57 0.10 mm) and the biggest size (12.25 0.20) were
observed in the Tween 80/Chol/CTAB and Span 60/
Tween 60/Chol/CTAB vesicles, respectively (Table 1). The
mean volume diameters were significantly increased by
adding Tween to Span formulations (p5 0.05).
With the exception of span 20/Chol/CTAB formulation,
the mean volume diameter of niosomes increased by
increasing in the hydrophilic–lipophilic balance (HLB)
value from Span 80 (HLB 4.3) to Span 60 (HLB 4.7) and
Span 40 (HLB 6.7) (Table 1). The same result was reported
about niosomes composed of sorbitan monoesters (Span
20, 40, 60 and 80) or a sorbitan triester (Span 85). These
results might be anticipated since surface-free energy
decreases with the increase in hydrophobicity (Yoshioka
et al., 1994).
The change in particle size as a major indicator for nio-
some stability during storage at 4C for 3 months was
exhibited in Table 1. Furthermore, precipitation of the
membrane components was evaluated by microscopic
observation. Lawrence et al. (1996) suggested that size
increment was due to fusion of the membranes and
growth rather than vesicle aggregation. To avoid this
effect, in our study, we used electrostatic repulsion
among vesicles using the positively charged surfactant.
Niosomes prepared from solid-state surfactants (Span 40
and 60), exhibited lower change in particles size and were
morphologically more stable than Span 20 and 80 formu-
lations under storage conditions. These significant alter-
ations in stability markers may result from the fluidity of
Span 20 and 80 bilayers leading to more leaky and unstable
structure. Microscopic observation also revealed the for-
mation of the needle-like and plate crystals in these formu-
lations. This effect was previously reported about the
niosomes containing insulin and tretinoin prepared by
Span 80 (Manconi et al., 2002; Varshosaz et al., 2003).
Except for Span 60, which was stable after 3 months, addi-
tion of Tweens to Span formulations significantly improved
the particle size stabilities of all formulations during stor-
age conditions (p5 0.05). This stability may be due to
steric stabilization following surface modification of nio-
somes by polyoxyethylene derivatives. As an example, the
size distribution curves of niosomes containing Span 20/
Chol/CTAB and Span 20/Tween 20/Chol/CTAB after 72 h
and 3 months were shown in Figure 2(a) and (b),
respectively.
The niosome components play a critical role in EE% of
protein antigens. EE% of influenza antigens formulated in
Span 40 or 60/Chol/dicetyl phosphate was between 14%
and 23% (Chattaraj and Das, 2003). Furthermore, for BSA
and haemagglutinin formulated in niosomes prepared by
Span 60, Chol and Solulan C24, the reported EE% was 30%
(Murdan et al., 1999). ALM is composed of various soluble
and insoluble compounds. Thus, it should be able to enter
into a vesicular structure both in the lipophilic bilayer and
in the hydrophilic core. The percentage of ALM entrapped
in all niosome formulations varied between 14.88% and
36.65% (Table 1). Tween 20/Chol/CTAB niosomes had
the lowest amount of entrapped ALM (Table 1). This
effect may be due to these facts that surfactants with
HLB510 can better shape niosomes than other surfactants
(Varshosaz et al., 2005) and Tween 20 had the highest HLB
among the surfactants used in this study (HLB 16.7). Except
for Tween 20 formulation, the EE% in Tween 80/Chol/
CTAB is significantly lower than other niosomes
(p5 0.05) (Table 1). The alkyl chain in Tween 80 is unsat-
urated, which leads to leaky bilayers in niosomes and low
EE%. No significant difference was observed between EE%
data for the niosomal formulations composed of Span/
Chol/CTAB and Span/Tween /Chol/CTAB (p4 0.05).
Formerly insufficient effect of using ALM with BCG at
single dose against leishmaniasis was reported (Sharifi
et al., 1998). Thus, the researcher used other methods for
Figure 1. Optical micrographs (1000 magnification) of ALM-containing
niosomes prepared by film hydration method. Niosomes were composed
of (a) Span 20/Chol/CTAB (6:3:1 molar ratio) and (b) Span 40/Tween 40/
Chol/CTAB (3:3:3:1 molar ratio), Scale bar¼ 10 mm.
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vaccination such as the use of multiple doses of ALM with
BCG vaccine (Alimohammadian et al., 2002) and the com-
bination of ALM with interleukin-12 (Kenney et al., 1999).
In this study, we employed multiple doses of ALM
entrapped in positively charged niosomes for stimulating
the immune response against cutaneous leishmaniasis in
mice. Based on the physicochemical studies, the Span 40/
Tween 40/Chol/CTAB formulation showed enough EE%
and particle size stability was preferred for in vivo experi-
ment. The results of in vivo studies were shown in Figure 3.
In control and niosomes without ALM group, the lesions
were progressively developed after 4 weeks and all animals
showed lesions after 18 weeks of infection (Figure 3). The
mean lesion sizes at different time points of infection in
control group were not significantly different from nio-
somes without ALM group (p4 0.05). Thus the presence
of ALM as an antigen is a critical factor for stimulating the
immune response. In ALM and niosomes containing ALM
groups, the lesions were developed after 4 and 7 weeks,
respectively. The mean lesion size in niosomes contain-
ing ALM group was significantly different from control,
ALM and niosomes without ALM groups (p5 0.05).
Although these results exhibited that the niosomes con-
taining ALM can successfully delay the development of
lesions and decrease the lesions size in contrast to
ALM, unfortunately, this formulation cannot completely
prevent cutaneous leishmaniasis. Such a delay in the
development of lesions may be due to these fact that
the niosomes can prevent the rapid degradation of anti-
gens and act as a slow releasing source of antigens to
immune cells (Nakanishi et al., 1997). Furthermore,
antigen-presenting cells have more tendency to phago-
cyte the positively charged vesicles and present the
incorporated antigens to other immune cells
(Nakanishi et al., 1997). These effects might be very
important in the prevention and delay the development
of lesions produced by L. major. It seems that using
the new antigens, improving the niosomal formulations
and determining the immune response type (by mea-
suring different interleukins), in future, it will be possi-
ble to design the new immunological adjuvant for
better prevention of cutaneous leishmaniasis.
Conclusions
ALM was successfully entrapped within the lipid bilayers of
the vesicles with high efficiency. Sorbitan ester niosomes
had higher EE% in comparison to polysorbate niosomes. By
adding Tween to Span formulation, the EE% of ALM was
partially decreased in some formulations but stability was
increased. The obtained data provide direct evidence that
the combination of electrostatic repulsion and steric stabi-
lization can improve the stability of niosomes. In contrast
to ALM, Span 40/Tween 40/Chol/CTAB containing ALM
has a moderate effect in the prevention of cutaneous leish-
maniasis and can successfully delay the development of
lesions in BALB/c mice.
Figure 2. The vesicle size distribution of ALM-containing niosomes at different time intervals after preparation. Niosomes were composed of (a) Span
20/Chol/CTAB (6:3:1 molar ratio) and (b) Span 20/Tween 20/Chol/CTAB (3:3:3:1 molar ratio).
Figure 3. The effect of subcutaneous vaccination by PBS (pH 7.2) (control
group), ALM, niosomes without ALM and niosomes containing ALM
against cutaneous leishmaniasis in BALB/c mice.
Note: Data are expressed as the mean SD, (n¼ 8), the number of mice
which developed lesions is indicated after each line.
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